Regulatory T Cell Formation Regulatory T Cell

Mandy Pierau, Swen Engelmann, Dirk Reinhold, Thabo Lapp, Burkhart Schraven and Ursula H. Bommhardt J Immunol 2009; 183:6124-6134; Prepublished online 19 October 2009; doi: 10.4049/jimmunol.0900246 http://www.jimmunol.org/content/183/10/6124

References Subscriptions Permissions Email Alerts

This article cites 74 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/183/10/6124.full#ref-list-1 Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscriptions Submit copyright permission requests at: http://www.aai.org/ji/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/cgi/alerts/etoc

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 9650 Rockville Pike, Bethesda, MD 20814-3994. Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.

Downloaded from http://jimmunol.org/ at Medizinische Zentralbibliothek Magdeburg on January 23, 2013

This information is current as of January 23, 2013.

Protein Kinase B/Akt Signals Impair Th17 Differentiation and Support Natural Regulatory T Cell Function and Induced Regulatory T Cell Formation

The Journal of Immunology

Protein Kinase B/Akt Signals Impair Th17 Differentiation and Support Natural Regulatory T Cell Function and Induced Regulatory T Cell Formation1 Mandy Pierau,2 Swen Engelmann,2 Dirk Reinhold, Thabo Lapp, Burkhart Schraven, and Ursula H. Bommhardt3

R

egulatory T cells (Tregs)4 play a key role in controlling the immune response of peripheral CD4⫹ T cells and, thereby, in maintaining peripheral tolerance (1). Thymus-derived natural CD4⫹CD25⫹ Tregs (nTregs) constitute ⬃5– 10% of the peripheral CD4⫹ T cell pool. They constitutively express CD25, the ␣-chain of the high-affinity IL-2 receptor, and IL-2 is a key regulator in the function and homeostasis of nTregs. Along with TCR and CD28 costimulation, high doses of IL-2 have been used to expand Tregs. For murine T cells, the transcription factor Foxp3 is a definitive lineage-specific marker and ectopic expression of Foxp3 was shown to be sufficient to convert con-

Institute of Molecular and Clinical Immunology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany Received for publication January 22, 2009. Accepted for publication September 8, 2009. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1

This work was supported by grants from the Deutsche Forschungsgemeinschaft (BO1054/2-1) and Land Sachsen-Anhalt (N2/ND; to U.B.).

2

M.P. and S.E. contributed equally to this work and should be considered co-first authors.

3

Address correspondence and reprint requests to Dr. Ursula Bommhardt, Institute of Medical and Clinical Immunology, Otto-von-Guericke University Magdeburg, Leipzigerstrasse 44, D-39120 Magdeburg, Germany. E-mail address: ursula.bommhardt@ med.ovgu.de

4

Abbreviations used in this paper: Treg, regulatory T cell; iTreg, induced Treg; nTreg, natural Treg; PKB, protein kinase B; myrPKB, myristoylated PKB; tg, transgenic; Teff, effector T cell; EAE, experimental autoimmune encephalomyelitis; mTOR, mammalian target of rapamycin; wt, wild type; pERK, phosphorylated ERK; MOG, myelin oligodendrocyte glycoprotein; IFR4, IFN regulatory factor 4; MFI, mean fluorescence intensity; GITR, glucocorticoid-induced TNFR-related protein; ROR␥t, retinoid-related orphan receptor gamma; PTEN, phosphatase and tensin homologue. Copyright © 2009 by The American Association of Immunologists, Inc. 0022-1767/09/$2.00

www.jimmunol.org/cgi/doi/10.4049/jimmunol.0900246

ventional CD4⫹CD25⫺ T cells to Tregs by conferring a sustained suppressive activity (2– 4). In the periphery, CD4⫹Foxp3⫹ Tregs can be induced by a low dose of Ag and limited costimulatory signals (5–9). TGF-␤ is essential to maintain Foxp3 expression and peripheral nTreg function (10). In concert with TCR and CD28 signals, TGF-␤ is also a potent inducer of suppressive function in naive T cells and, therefore, of inducible Tregs (iTregs) (6, 11). TGF-␤ exerts its biological activities through the transcriptional regulation of numerous genes. Its activity is transmitted through the TGF-␤ receptors type I and type II which, in turn, induce the formation of pSmad2, pSmad3, and Smad4 complexes, the intracellular key mediators of TGF-␤ signaling (12). However, the molecular mechanisms through which TGF-␤ signals control T cell differentiation and function are not well characterized. TGF-␤ signals also play a key role in the generation of Th17 cells. The production of IL-17 is associated with host defense against infectious agents and the development of autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE), in which Th17 cells promote inflammatory responses. IL-6 in the presence of TGF-␤ facilitates Th17 differentiation, but interestingly hampers differentiation of naive T cells to Foxp3⫹ cells (13, 14). Thus, the generation and function of iTregs and Th17 cells are reciprocally regulated and share TGF-␤ as a common inducer. Relatively little is known about the intracellular signaling mechanisms regulating Treg development and function (15–17). One important pathway downstream of TCR and CD28 signaling is the PI3K/protein kinase B (PKB)/mammalian target of rapamycin (mTOR) pathway, which regulates survival, growth, and differentiation processes in conventional T cells (18 –22). This signaling cascade also appears to be central in the formation and function of nTregs. For instance, CD28 signaling has been found to be important for Treg development in the thymus (23) and to control the


Protein kinase B (PKB)/Akt signals control T cell proliferation and differentiation but their effect on the generation and function of regulatory T cells (Treg) and Th17 cells is not well understood. In this study, we show that elevated PKB signals antagonize the immunosuppressive effect of TGF-␤1 on cell size, CD25 and CD98 expression, and proliferation of CD3-stimulated naive CD4ⴙ T cells from wild-type and CD28-deficient mice. Conventional CD4ⴙ T cells expressing active PKB are less susceptible to suppression by natural regulatory T cells. Although PKB signals do not affect the development of natural regulatory T cells, they enhance their suppressor capacity. Upon TCR triggering and TGF-␤1 costimulation, wild-type and CD28-deficient CD4ⴙ T cells transgenic for PKB readily express Foxp3, thereby acquiring suppressor capacity. These effects of elevated PKB signals on T cell function involve a marked and sustained activation of STAT5 and Foxp3 and reduction in nuclear NFATc1 levels. In contrast, PKB signals impair TGF-␤1/IL-6-mediated differentiation of naive CD4ⴙ T cells into the Th17 lineage. This correlates with an increased signaling of ERK, STAT5, and STAT6. Finally, elevated PKB signals reduced the severity of experimental autoimmune encephalomyelitis in wild-type mice but induced experimental autoimmune encephalomyelitis in mice deficient for CD28. Altogether, these data indicate an important role of PKB signals on control of TGF-␤1-mediated T cell responses and, thereby, on tolerizing and inflammatory immune processes. The Journal of Immunology, 2009, 183: 6124 – 6134.


Materials and Methods Mice Heterozygous myrPKB transgenic (PKB tg) mice (on C57/BL6 background) expressing constitutively active huPKB␣ (37) and Foxp3-GFP knock-in (Foxp3-GFP) mice (39) were described previously. CD28-deficient (CD28⫺/⫺) mice were provided by Dr. F. Lu¨hder (University of Go¨ttingen, Go¨ttingen, Germany). Wild-type, PKB tg, CD28⫺/⫺, and PKB tg CD28⫺/⫺ mice were crossed with Foxp3-GFP mice, provided by Dr. A. Rudensky (University of Seattle, Seattle, WA), to obtain mice homozygous for Foxp3-GFP alleles. Mice used for experiments were 6 –10 wk old and in case of EAE experiments 10 –12 wk.

Abs, reagents, and intracellular staining Abs for cell stimulation, cell isolation, and flow cytometry were obtained from BD Biosciences: CD4 (GK1.5), CD25 (7D4), and CTLA4 (UC104B9); Cell Signaling: pERK (Thr202/Tyr204); eBioscience: IL10-PE (JE5516E3), IL-17A-PE (ebio 17B7), IFN-␥-FITC (XMG1.2), IL-4-FITC (BVD6-24G2), and CD98-FITC (RL388); or Miltenyi Biotec: GITR-PE (DTA-1). For Foxp3 staining, an intracellular Foxp3 (FJK-16s) staining kit from eBioscience was used as described in the manufacturer’s protocol. Recombinant human TGF-␤1 was purchased from R&D Systems. For flow cytometric measurement of ERK activation, lymph node cells from wt and PKB tg mice were rested for 2 h at 4°C in RPMI 1640 medium; cells were activated with biotinylated CD3 (10 ␮g/ml) and CD28 (10 ␮g/ml) Abs and streptavidin (50 ␮g/ml; Jackson ImmunoResearch Laboratories/Dianova). At the indicated time points, cells were fixed and lysed with the Fix Perm buffer from eBioscience and stained for Foxp3, phosphorylated ERK (pERK), and CD4. Expression of pERK in gated CD4⫹Foxp3⫹ and CD4⫹Foxp3⫺ cells was analyzed by flow cytometry using a FACSCalibur and CellQuest Pro software (BD Biosciences).

Proliferation assay CD4⫹CD25⫺ T cells were isolated from pooled lymph nodes of several mice by negative selection using a mixture of biotinylated Abs: CD25 (PC61), NK1.1 (PK136), Ter-119, CD8␣ (53-6.7), I-A/I-E (2G9), CD45R/ B220 (RA3-6B2), CD11b (M1/70), and streptavidin magnetic beads (Miltenyi Biotec) according to the manufacturer’s protocol. Purity of CD4⫹CD25⫺ T cells was above 95%. CD4⫹CD25⫺ T cells were cultured in triplicates on plates coated with CD3 Ab (145.2C11) or CD3 plus CD28 (37.51) Abs in concentrations as indicated in complete RPMI 1640 medium supplemented with 10% FCS, 50 ␮M 2-ME, and 1% penicillin/streptomycin. Proliferation was measured at 24 h of culture by [3H]thymidine incorporation (0.2 ␮Ci/well; MP Biomedicals) for 16 h. For nTreg proliferation assays, CD4⫹CD25⫹Foxp3⫹ and CD4⫹CD25⫺Foxp3⫺ cells from wt and PKB tg Foxp3-GFP mice were sorted by FACS; 1 ⫻ 105 cells were stimulated with plate-bound CD3/CD28 Abs (2 and 5 ␮g/ml) for 3 days in the presence or absence of IL-2 (100 ng/ml; Biochrom) when [3H]thymidine incorporation was measured for 8 h. Data give the mean of triplicates ⫾ SD. For cell cycle analysis, CD4⫹CD25⫺ T cells were labeled with 2 ␮M CFSE (Invitrogen) in RPMI 1640 medium for 5 min at room temperature, washed twice with RPMI 1640/10% FCS and cultured in supplemented RPMI 1640/10% FCS medium. CFSE dilution was measured on day 3 by flow cytometry.

Suppression assay CD4⫹CD25⫺ (T effector cells (Teffs)) and CD4⫹CD25⫹ (nTreg) cells from lymph nodes of wt or PKB tg mice were isolated with a Treg isolation kit from Miltenyi Biotec following the manufacturer’s instructions. The purity of isolated Tregs usually was above 90%. For suppression assays, 1 ⫻ 105 Teffs were cocultured with CD4⫹CD25⫹ cells at the indicated ratio and 1 ⫻ 105 irradiated (30 Gy) wt splenocytes in the presence of soluble CD3 Ab (2 ␮g/ml) for 3 days, when proliferation was determined by [3H]thymidine incorporation.

Treg and Th17 induction CD4⫹CD25⫺ T cells from wt, PKB tg, CD28⫺/⫺, and PKB tg CD28⫺/⫺ mice were isolated to above 95% purity. Three ⫻ 106 CD4⫹CD25⫺ T cells were cultured on CD3 Ab (2 ␮g/ml)- or CD3/CD28 Ab (2 and 5 ␮g/ml)coated plates with or without TGF-␤1 (10 ng/ml). On day 3, cells were harvested and analyzed for the expression of Foxp3, CD25, and glucocorticoid-induced TNFR-related protein (GITR) by flow cytometry. For the induction of Th17 cells, CD4⫹CD25⫺ cells were cultured with CD3/CD28 Abs and TGF-␤1 (10 ng/ml) in the presence or absence of IL-6 (20 ng/ml; eBioscience). On day 3, cells were restimulated with PMA and ionomycin (100/800 ng/ml; Calbiochem) in the presence of brefeldin A (2 ␮g/ml; Calbiochem) for 4 h and analyzed for the expression of Foxp3, IL-17, IFN-␥, IL-4, or IL-10. For suppression assays with iTregs, CD4⫹CD25⫺ T cells from wt and PKB tg Foxp3-GFP mice were stimulated with CD3 Ab (2 ␮g/ml) or CD3/CD28 Abs (2 and 5 ␮g/ml) and TGF-␤1 (10 ng/ml) for 3 days. Induced Foxp3⫹ wt and PKB tg cells were sorted by FACS and cocultured for 3 days with 1 ⫻ 105 wt CD4⫹CD25⫺ Teff cells at the indicated ratio, CD3 Ab (2 ␮g/ml) and 2 ⫻ 105 irradiated splenocytes. Proliferation was determined by [3H]thymidine incorporation.

EAE induction Wild-type, PKB tg, CD28⫺/⫺, and PKB tg CD28⫺/⫺ mice were immunized with 200 ␮g of myelin oligodendrocyte (MOG) peptide p35–55 (MOG35–55 peptide) in CFA (Sigma-Aldrich) containing 800 ␮g of heatkilled Mycobacterium tuberculosis (Difco Laboratories). A volume of 50 ␮l was injected s.c. at four sites over the flanks; 200 ng of pertussis toxin (List Biological Laboratories) dissolved in 200 ␮l of PBS was injected i.p. on the day of immunization and 2 days later. Clinical signs of EAE were monitored daily and scored by the following criteria: 0, no signs of disease; 0.5, partial loss of tail tonus; 1, limp tail; 1.5, limp tail and slight slowing of righting; 2, partial paresis of one hind limb and/or marked slowing of righting; 2.5, dragging of hind limb(s) without total paralysis; 3, complete paralysis of at least one hind limb; 4, severe forelimb weakness; and 5, moribund or dead (40). Animal experiments were approved by the local state authorities; mice with a clinical score above 2.5 were killed according to the animal statutes.

Western blot analysis Five ⫻ 106 CD4⫹CD25⫺ T cells were stimulated for the indicated time points on plates coated with CD3 Ab (3 ␮g/ml) or CD3/CD28 Abs (2 and 5 ␮g/ml) in the presence or absence of TGF-␤1 (10 ng/ml) and IL-6 (20 ng/ml). Harvested cells were lysed as described previously (38) to obtain


homeostasis of peripheral Tregs (24 –26). PI3Kp110␦D910〈/D910〈 knock-in mice expressing an inactive PI3K␦ isoform showed an enhanced generation of nTregs in thymus, but peripheral p110␦D910〈/D910〈 nTregs were less abundant (27). For peripheral human nTregs, a reduced capacity to activate PKB was described previously (28) and retroviral expression of active PKB in human Treg cell lines inhibited their suppressive capacity. Expression of phosphatase and tensin homologue (PTEN), the negative regulator of PI3K-induced PIP3 signaling, was found to be down-regulated after T cell activation, whereas relatively higher levels were detected in CD4⫹CD25⫹ Tregs (15, 29). However, in mice bearing inactive PTEN alleles in the T cell compartment, nTregs developed normally and showed a normal suppressor function (30). More recently, the retroviral expression of an active version of PKB was reported to impair de novo Foxp3 expression and nTreg development in the thymus (31). Likewise, by applying pharmacological inhibitors, a reduced PI3K/PKB signaling enhanced the induction of Foxp3 in TCR-primed T cells (32) and the immunosuppressant rapamycin, which inhibits mTOR activity and is a downstream target of PKB signaling, fostered Foxp3 expression, and Treg expansion (33). In view of the emerging developmental and functional plasticity of Th17 and Treg cells (34, 35) and that CD4⫹ T cells expressing a constitutively active version of PKB␣, myristoylated PKB (myrPKB), show increased TCR responsiveness and are less susceptible to suppression by the immunosuppressant cyclosporin A (36 –38), we studied the effect of myrPKB on TGF-␤ signaling and effector function, i.e., the generation and function of Tregs and Th17 cells. We demonstrate that elevated PKB signals reduce the susceptibility of conventional CD4⫹ T cells to nTreg-mediated suppression, enhance nTreg suppressor function, and replace the requirement for CD28 signals for induction of peripheral iTregs from CD4⫹CD25⫺ cells. Furthermore, elevated PKB signals impair TGF-␤/IL-6-mediated Th17 differentiation and alter the severity of EAE disease in wild-type (wt) and CD28⫺/⫺ mice. Taken together, the results reveal an important function for PKB in balancing autoimmune and inflammatory immune responses.

6125

6126

PKB/Akt INFLUENCES Th17 AND Treg PHYSIOLOGY

cytoplasmic and nuclear protein extracts. Protein concentration was determined by bicinchoninic acid reagent (Pierce) and 10 –25 ␮g of protein lysate was run on 8 –10% SDS-PAGE. After transfer to nitrocellulose membranes, expression of the indicated proteins was analyzed with the following primary Abs: pSmad3/1 (Smad3 Ser423/425, Smad1 Ser463/465), pSmad2 (Ser245/250/255), Smad4, pSTAT5 (Tyr694), pSTAT3 (Tyr705), pSTAT1 (Tyr701), pSTAT6 (Tyr641), pERK (Thr202/Tyr204), pAkt (S473), panAkt (C67E7), pS6 (S240/244), pGSK3␤ (Ser9, 5B3), pTSC2 (Thr1462) (all from Cell Signaling), ␤-actin (AC-40; Sigma-Aldrich), NFATc1 (7A6; Alexis Biochemicals), Foxp3 (150D/E4), retinoid-related orphan receptor gamma (ROR␥t) (B2D; both eBioscience), IFN regulatory factor 4 (IRF4, AA.128-267; Santa Cruz Biotechnology). Primary Abs were detected with HRP-coupled goat anti-mouse, mouse anti-rabbit, or donkey anti-goat Abs (Jackson ImmunoResearch Laboratories/Dianova) and the ECL detection system (Pierce). Western blot analysis of wt and PKB tg nTregs and CD4⫹CD25⫺ T cells was performed with total protein extracts from 1 ⫻ 106 cells isolated by FACS sorting or with a Treg isolation kit from Miltenyi Biotec.

Statistical analysis Statistical differences in cell percentage, cell number, and proliferation values were analyzed using Student’s t test. Statistical analysis of EAE disease score was performed with the nonparametric Wilcoxon two-sample test (41). A p ⬍ 0.05 was considered statistically significant.

Results PKB signals abrogate TGF-␤1-induced suppression of proliferation of naive CD4⫹ T cells Whereas TGF-␤, as a negative regulator of immune function, inhibits TCR-mediated signaling and proliferation, PKB signals enhance cell cycle progression, cytokine production, and cell growth. Due to this functional antagonism, we analyzed the effect of a constitutively active form of PKB␣ (myrPKB) on TGF-␤1-mediated suppression of proliferation of CD4⫹ T cells from wt and myrPKB tg (PKB tg) mice (37). Naive cells from those mice were

activated with CD3 Ab in the presence of 0.1–10 ng TGF-␤1 and their proliferation was measured after 24 h. Intriguingly, whereas wt T cells were inhibited by low doses of TGF-␤1 (0.1–1.0 ng), CD3-induced proliferation of PKB tg T cells remained unaffected, even by high TGF-␤1 doses (10 ng; Fig. 1A). This shows that PKB signals can abrogate the inhibitory proliferative signals generated by TGF-␤1 after TCR ligation. Proliferation of wt T cells costimulated by CD3/CD28 Abs was refractory to TGF-␤1 inhibition, similar to PKB tg T cells stimulated in the same manner (Fig. 1B). Analysis of cell cycle progression by CFSE dilution assays extended these results. Treatment with CD3 Ab for 3 days induced vigorous cell cycling and four cell divisions in wt and PKB tg T cells (Fig. 1C). In the presence of TGF-␤1 only a small fraction (18%) of wt T cells cycled once, whereas cell division of PKB tg T cells was hardly affected. Again, division of wt cells costimulated by CD28 Ab was refractory to TGF-␤1 inhibition and similar to PKB tg cells. Although having extensively cycled, wt and PKB tg cells showed a strong reduction in forward side scatter in the presence of TGF-␤1 (Fig. 1C, left panels), suggesting that TGF-␤1 signals lead to a down-regulation of cell metabolism affecting cell size. Whereas wt T cells treated with CD3 Ab plus TGF-␤1 were extremely small, PKB tg cells were of moderate cell size, indicating that PKB signals, like CD28 costimulation in wt cells, maintain cell growth at a reduced level in the presence of TGF-␤1. In this context, we analyzed the expression of CD25 and CD98, indicators for the extent of T cell activation and amino acid uptake (42, 43). Pronounced differences between wt and PUB tg cells became apparent at day 2 of culture (Fig. 1D). Cells treated with TGF-␤1 showed markedly lower CD25 expression than untreated cells, but CD25 expression on CD3/CD28-costimulated cells was significantly higher than that on cells treated with CD3 Ab only. Under


FIGURE 1. Elevated PKB signals abrogate TGF-␤1-induced inhibition of proliferation of wt and CD28⫺/⫺ CD4⫹ T cells. CD4⫹ T cells from wt and PKB tg mice (A–D) and CD28⫺/⫺ and PKB tg CD28⫺/⫺ mice (E and F) were stimulated with CD3 Ab (3 ␮g/ml) or CD3 ⫹ CD28 Abs (3 and 5 ␮g/ml) without or in the presence of TGF-␤1 (10 ng/ml) or in concentrations as indicated. Proliferation in A, B, and E was assessed after 24 h by [3H]thymidine incorporation and is given as cpm ⫹ SD. C and F, Cell division of CFSE-labeled CD4⫹ T cells was analyzed on day 3 by flow cytometry. The number of cell divisions is indicated in the histograms. Left panels in C show the forward scatter of wt and PKB tg cells at day 3. D, CD25 and CD98 expression of wt and PKB tg CD4⫹ T cells was analyzed on day 2 by flow cytometry. Data are representative of two to three experiments.


6127

all stimulatory conditions, PKB tg cells showed higher CD25 expression, which was less affected by TGF-␤1. Concerning CD98 expression, the highest levels were observed in CD3/CD28-costimulated T cells and expression was similar for wt and PKB tg cells treated either with CD3 or CD3 plus CD28 Abs. TGF-␤1 led to a reduction in CD98 expression, but levels were found to be significantly higher in PKB tg cells. These data indicate that similar to CD28 costimulation, elevated PKB signals keep CD25 and CD98 expression at intermediate levels and override TGF-␤1-mediated inhibition of cell division after stimulation with CD3 Ab. Since CD28-deficient (CD28⫺/⫺) T cells are less responsive to TCR stimulation (44), we asked whether PKB signals can replace CD28 costimulatory signals and antagonize TGF-␤1-mediated inhibition. To answer this question, CD4⫹ T cells from CD28⫺/⫺ and PKB tg CD28⫺/⫺ mice were stimulated with CD3 Ab plus TGF-␤1 and DNA synthesis and cell cycle progression were measured at day 1 or day 3, respectively. As shown in Fig. 1E, proliferation of CD28⫺/⫺ CD4⫹ T cells (measured at 24 h) was inhibited by low doses of TGF-␤1 (0.1 ng), whereas PKB tg CD28⫺/⫺ CD4⫹ T cells significantly proliferated even in the presence of 10 ng of TGF-␤1. Likewise, analysis of cell division by CFSE dilution (Fig. 1F) revealed that in response to CD3 Ab stimulation PKB tg CD28⫺/⫺ cells not only proliferated better than CD28⫺/⫺ cells but, importantly, they showed a significant expansion and progression through three cell cycles in the presence of TGF-␤1, comparable to CD28⫺/⫺ cells stimulated with CD3 Ab. In contrast, cell division of CD28⫺/⫺ cells was completely inhibited by TGF-␤1/CD3 treatment. CD3/CD28 costimulation served as a control for CD28 deficiency and CFSE profiles as expected were identical to CD3-treated cells. These data indicate that PKB signals can alter the outcome of TGF-␤1 signaling in the absence of CD28 signaling and, therefore, can replace missing CD28 signals. Elevated PKB signals foster expansion of nTregs along with CD4⫹ T cells but cannot fully replace CD28 signals for the generation of nTregs Since the generation and homeostasis of natural regulatory CD4⫹ CD25⫹ T cells (nTregs) is supported by CD28 signaling (23, 24),

the data presented above suggest that elevated PKB signals might support nTreg formation. Using mice bearing Foxp3-GFP alleles (3), we analyzed nTreg development in wt, PKB tg, as well as CD28⫺/⫺ and PKB tg CD28⫺/⫺ mice. As shown in Fig. 2A, the majority of CD25⫹ cells in wt and PKB tg mice were positive for Foxp3, a marker for murine Tregs (2– 4). However, the percentage of CD25⫹Foxp3⫹ nTregs within the CD4⫹ population of thymus, spleen, and lymph nodes from PKB tg mice was comparable to that of wt mice, albeit there was an ⬃2-fold increase in the absolute number of Foxp3⫹ nTregs in the organs of PKB tg mice (Fig. 2B), indicating that along with conventional CD4⫹ T cells (37) PKB signals support expansion of nTregs. In CD28⫺/⫺ mice, a reduction was observed in the proportion of nTregs in thymus, spleen, and lymph nodes (Fig. 2C). Although myrPKB expression in CD28⫺/⫺ mice led to an increase in the percentage and cell number of CD4⫹ T cells and an ⬃2-fold increase in CD28⫺/⫺ nTregs in thymus, lymph nodes, and spleen, the absolute number of nTregs in PKB tg CD28⫺/⫺ mice was still less than half of that in wt mice (Fig. 2D). This shows that tg PKB signals exert a limited effect on the generation of nTregs and cannot fully replace CD28 signals in nTreg formation. PKB signals enhance the suppressive capacity of nTregs To examine the effect of active PKB on nTreg function, we performed cocultures of conventional CD4⫹CD25⫺ T cells and nTregs from wt or PKB tg mice in various combinations and ratios for the determination of proliferation by [3H]thymidine incorporation. Two remarkable effects of enhanced PKB signals on nTregmediated suppression were observed: 1) PKB tg nTregs inhibited the proliferation of wt effector cells more efficiently than wt nTregs (Fig. 3A, f) and 2) CD4⫹CD25⫺ effector cells from PKB tg mice were more resistant to suppression than those from wt mice by both wt or PKB tg nTregs (Fig. 3A, cf o with f). At ratios of 5:1 and 10:1 of effector to suppressor cells, PKB tg effector cells proliferated 1.5– 4 times better than wt effector cells, indicating that the former are less inhibited by nTregs. In contrast, we did not observe a marked difference in suppression of PKB tg effector cells by either wt or tg nTregs. These experiments allow the conclusion that elevated PKB signals enhance 1) the suppressor function of


FIGURE 2. Elevated PKB signals expand CD4⫹ and nTreg cell number in wt and CD28⫺/⫺ mice. Cells were stained for CD4, CD8, and CD25 expression and analyzed by flow cytometry. A, Distribution of CD4⫹CD25⫹Foxp3⫹ cells in thymus (n ⫽ 7 mice), lymph nodes, and spleen (n ⫽ 4 mice each) from wt and PKB tg Foxp3-GFP mice. B, Absolute cell number of CD4⫹ and CD4⫹CD25⫹Foxp3⫹ cells in the organs of the indicated mice. C, Distribution of CD4⫹CD25⫹Foxp3⫹ cells and D, absolute cell number of CD4⫹ and CD4⫹CD25⫹Foxp3⫹ cells in thymus, lymph nodes, and spleen from wt, CD28⫺/⫺, and PKB tg CD28⫺/⫺ Foxp3-GFP mice (n ⫽ 4 mice each); ⴱ, p ⬍ 0.05 and ⴱⴱⴱ, p ⬍ 0.001.

6128


PKB signals enhance Foxp3 expression and iTreg formation

FIGURE 3. Active PKB decreases the susceptibility to Treg suppression and enhances Treg function. A, CD4⫹CD25⫺ Teff cells of wt and PKB tg mice were cocultured with wt or PKB tg CD4⫹CD25⫹ nTregs in the indicated ratios in the presence of irradiated splenic cells and stimulated to proliferate by CD3 Ab for 72 h. Proliferation was measured by [3H]thymidine incorporation. The results are representative of three independent experiments; ⴱ, p ⬍ 0.05; ⴱⴱ, p ⬍ 0.01; and ⴱⴱⴱ, p ⬍ 0.001. B, FACS-sorted CD4⫹CD25⫹Foxp3⫹ and CD4⫹CD25⫺Foxp3⫺ T cells from wt and PKB tg Foxp3-GFP mice were stimulated with CD3/CD28 Abs in the absence or presence of IL-2. On day 3, proliferation was assessed by [3H]thymidine incorporation. Data are representative of two experiments. C, Expression of GITR and CTLA4 on wt (thin black line) and PKB tg (thick black line) nTregs; the gray line shows staining with isotype control Ab. The indicated MFI shows the average from four mice: wt 75 ⫾ 7.5, PKB tg 40 ⫾ 3.3; ⴱⴱⴱ, p ⬍ 0.001. Results are representative of three experiments. D, wt and PKB tg nTregs and CD4⫹CD25⫺ cells were analyzed for expression/phosphorylation of the indicated proteins by Western blot. Results are representative of three experiments. E, Intracellular expression of pERK in wt and PKB tg CD4⫹Foxp3⫹ cells prior (0 min, thin black lines) and after stimulation with CD3/CD28 Abs for 1 min (thick fat black lines) and 10 min (broken lines) was determined by flow cytometry. Gray lines show staining with isotype control Ab. MFI values for pERK in the experiment shown were for wt cells: t0 ⫽ 27, t1 ⫽ 34, and t10 ⫽ 28 and for PKB tg cells t0 ⫽ 23, t1 ⫽ 53, and t10 ⫽ 33; MFI values from three experiments were ⌬t1–t0: wt, 10 ⫾ 4; PKB tg, 14 ⫾ 7, p ⫽ 0.43; and ⌬t10–t0: wt, 2 ⫾ 2; PKB tg, 9 ⫾ 3; ⴱ, p ⫽ 0.03.

We investigated next whether TCRplus TGF-␤1 signals could drive PKB tg T cells into Treg development in the absence of CD28 costimulatory signals. In these assays, we stimulated wt and PKB tg CD4⫹CD25⫺ T cells with CD3 Ab plus TGF-␤1 alone or along with CD28 Ab. When these cultures were analyzed for CD25 and Foxp3 expression on day 3, we observed 14% CD25⫹Foxp3⫹ cells in wt cultures but a substantial increase of CD25⫹Foxp3⫹ cells, 57%, in PKB tg cell cultures. After CD3 plus CD28 Ab stimulation in the presence of TGF-␤1, 62% of wt and 50% of PKB tg cells were CD25⫹Foxp3⫹ (Fig. 4, A and B). This indicates that in concert with CD3 plus TGF-␤1 signals PKB supports Foxp3 expression. Accordingly, after CD3 plus TGF-␤1 stimulation, PKB tg CD25⫹Foxp3⫹ cells showed a higher expression of the Treg markers CD25 and GITR compared with wt cells but similar to cells costimulated with CD3/CD28 Abs (Fig. 4A), indicating a strong delay in differentiation toward Tregs in wt cells. The number of CD25⫹Foxp3⫹ cells recovered after 3 days in culture under CD3 plus TGF-␤1 conditions was very low: compared with wt cells (0.7 ⫻ 105), an ⬃40-fold higher number of PKB tg cells (27.3 ⫻ 105) was found. After CD3 plus CD28 plus TGF-␤1 treatment, cell numbers were 23.4 ⫻ 105 for wt and 37 ⫻ 105 for PKB tg cultures. Thus, although the percentage of Foxp3⫹ cells in CD3/CD28 costimulated PKB tg cultures was reduced by ⬃12%, cell numbers for Foxp3⫹ cells were above those from wt cultures. To extend these results, we analyzed differentiation of CD4⫹CD25⫺ T cells from CD28⫺/⫺ and PKB tg CD28⫺/⫺ mice under identical culture conditions (Fig. 4, A and B). The percentage and cell number of CD28⫺/⫺CD25⫹Foxp3⫹ cells induced by CD3 plus TGF-␤1 was similar to those of wt cells. Strikingly, PKB signals enabled the efficient differentiation of CD28⫺/⫺CD4⫹ CD25⫺ T cells into the Treg lineage. These data show that PKB signals are as potent as CD28 costimulation in iTreg differentiation driven by CD3 plus TGF-␤1 signals in vitro.


nTregs and 2) the resistance of Teff cells against nTreg suppression. Since one hallmark of Treg cells is their low responsiveness against antigenic stimuli in vitro (1), we asked whether this is altered in nTregs from PKB tg mice. Similar to wt nTregs, nTregs from PKB tg mice did not significantly respond to IL-2 or CD3/ CD28 Ab stimulation alone, but upon addition of exogenous IL-2 to cultures stimulated by CD3/CD28 Abs, both nTreg populations proliferated robustly and equally well (Fig. 3B). The corresponding CD4⫹CD25⫺ cells reacted to CD3/CD28 Ab stimulation alone and IL-2 addition did not significantly enhance this effect. Hence, nTregs from PKB tg mice retain their hyporesponsiveness and dependence on CD3/CD28 plus IL-2 signals for their activation. To clarify to what extent tg PKB conveys downstream signals in nTregs, we analyzed the expression of the Treg markers GITR and CTLA4 and found similar expression of GITR for nTregs from wt and PKB tg mice (Fig. 3C), but levels of CTLA4 were reduced on PKB tg nTregs (mean fluorescence intensity (MFI) wt 75 ⫾ 7.5 vs MFI PKB tg 40 ⫾ 3.3), indicating specific effects of elevated PKB signals on the nTreg phenotype. Western blot analysis showed that nTregs from PKB tg mice express phosphorylated tg PKB and have higher levels of pGSK3␤ and pTSC2, but not of pS6, than wt nTregs (Fig. 3D). However, in comparison to the corresponding CD4⫹CD25⫺ cells, expression and signaling of tg PKB was reduced, indicating that in nTregs tg PKB signaling was attenuated. Also, after CD3/CD28 Ab activation the levels of pERK were found to be increased in PKB tg nTregs compared with wt nTregs (Fig. 3E).


6129

When we tested the suppressor activity of PKB tg Treg cells induced by CD3 plus TGF-␤1, indeed the cells had acquired suppressor function: they inhibited the proliferation of cocultured wt CD4⫹CD25⫺ cells as effectively as CD3/CD28 Ab-induced wt or PKB tg iTreg cells (Fig. 4C). Thus, along with TCR/TGF-␤1 triggering, elevated PKB signals are sufficient to induce a suppressive capacity in CD4⫹CD25⫺ T cells and, therefore, are able to generate iTregs. PKB signals sustain STAT5 signaling in naive CD4⫹ T cells To elucidate molecular mechanisms through which PKB signals might affect TGF-␤1 signaling, we investigated whether the expression of Smad proteins is affected in PKB tg T cells. Surprisingly, we did not observe substantial differences in the levels of cytosolic and nuclear pSmad2, pSmad3, and Smad4 proteins (Fig. 5) between wt and PKB tg T cells upon CD3/TGF-␤1 treatment, suggesting that PKB signals may act downstream of Smad activation or through other signaling pathways. In these studies, we made the interesting observation that CD3 Ab stimulation alone led to phosphorylation of Smad2 and nuclear

Smad4, whereas activation and nuclear localization of pSmad3 was strictly coupled to TGF-␤1 signals, suggesting that Smad2 and Smad4 exert important functions in T cell activation. Furthermore, the Western blot assays confirmed that, in concert with TGF-␤1 and CD3-only signals, elevated PKB signals foster the induction of Foxp3: at 40 h of stimulation by CD3 Ab plus TGF-␤1, a strong expression of Foxp3 was detectable in PKB tg but not wt T cells (see Fig. 5). Since Foxp3 induction was reported to be regulated by Smad3, NFAT, and STAT5 (45), we also investigated whether CD3 plus elevated PKB signals would affect the expression of these transcription factors. Whereas TGF-␤1 treatment of wt T cells stimulated with CD3 Ab only inhibited the nuclear accumulation of pSTAT5, PKB tg cells showed a pronounced expression of both cytoplasmic and nuclear pSTAT5, with levels above those seen after CD3 stimulation alone. Similarly, TGF-␤1, in relation to CD3 Ab stimulation, strongly diminished nuclear NFATc1 levels in wt cells, but to a lower degree in PKB tg cells, which overall show a reduced NFATc1 expression (Fig. 5A) (38). These data show that PKB plus TGF␤1 signals enhance STAT5 and reduce NFATc1 activation.


FIGURE 4. PKB signals enhance Foxp3 induction and the acquisition of a Treg phenotype. A, CD4⫹CD25⫺ T cells from wt, PKB tg, CD28⫺/⫺, and PKB tg CD28⫺/⫺ mice were stimulated for 3 days with TGF-␤1 (10 ng/ml) and either CD3 Ab (2 ␮g/ml) alone or with CD3/CD28 (2 and 5 ␮g/ml) Abs. The expression of CD25, Foxp3, and GITR was determined by FACS analysis. Percentage of CD25⫹Foxp3⫹ cells is indicated in the quadrants. Histograms show GITR expression of CD25⫹Foxp3⫹ cells from day 3 culture: thick line, PKB tg cells; thin line, wt cells; and gray line, isotype control. MFI for GITR expression is indicated. B, Percentage and cell number of CD4⫹CD25⫹Foxp3⫹ cells from 3-day cultures as described in A. Data show mean values ⫾SD from four experiments; ⴱⴱ, p ⬍ 0.01 and ⴱⴱⴱ, p ⬍ 0.001. C, CD4⫹CD25⫺ T cells from wt and PKB tg Foxp3-GFP mice were treated with TGF-␤1 and CD3 Ab or CD3 ⫹ CD28 Abs. At day 3, Foxp3⫹ cells (iTreg) were FACS sorted and cocultured with CD4⫹CD25⫺ wt Teff cells in the presence of irradiated splenic cells and CD3 Ab. Proliferation was determined by [3H]thymidine incorporation at day 3. The lower graph shows mean percent ⫹SD of suppression relative to the maximal proliferation of wt Teffs from three independent experiments.

6130

Because active PKB could replace CD28 signals in proliferation of CD4⫹ T cells (Fig. 1), we analyzed the expression of transcription factors in CD28⫺/⫺ and PKB tg CD28⫺/⫺ CD4⫹CD25⫺ T cells. Again, compared with CD28⫺/⫺ T cells and for the analyzed time points until 40 h, enhanced PKB signals in concert with TGF-␤1 signals and CD3 Ab stimulation only supported STAT5 phosphorylation and Foxp3 induction (Fig. 5B). This indicates that the activation of STAT5 and Foxp3, i.e., of two signaling molecules critical in the development of Treg cells, is inhibited or inefficient after CD3 plus TGF-␤1 stimulation of wt and CD28⫺/⫺ CD4⫹ T cells but can be compensated or strongly enhanced by elevated PKB signaling. PKB signals impair Th17 differentiation Since elevated PKB signals enhance Foxp3 expression, we asked whether PKB signals affect the production of IL-17 and the development of Th17 cells. When conventional CD4⫹ T cells induced by CD3/CD28 Abs were cultured with TGF-␤1 plus IL-6 for 3 days, IL-17 was produced in ⬃13% of wt cells but surpris-

ingly only in 3– 4% of PKB tg cells. Conversely, in TGF-␤1 plus IL-6 cultures, Foxp3 expression was found in 30% of PKB tg and in 12% of wt cells (Fig. 6A). In cell number, this translated into half the number of Th17 cells and 4.5 times more CD25⫹Foxp3⫹ cells in PKB tg vs wt cultures. Without IL-6 neither of the two induced cell types produced IL-17, instead both differentiated into Foxp3⫹ cells. Therefore, elevated PKB signals impair the formation of Th17 cells and foster differentiation into Foxp3⫹ cells. Whether elevated PKB signals also affect the production of other cytokines was analyzed by intracellular staining for IFN-␥, IL-4, and IL-10 (Fig. 6B). A low percentage of wt cells produced IFN-␥ (1.1%), IL-4 (1.5%), or IL-10 (3.8%). For PKB tg cells, the percentage of these cytokine-producing cells was increased by 2-fold and cell numbers 2- to 4-fold. Thus, the generation of cells producing IFN-␥, IL-10, or IL-4 was not markedly affected by PKB signals, but led to a slight increase in cell number. To get insight into the signaling events involved in the impaired Th17 differentiation of PKB tg T cells, we analyzed the expression of ROR␥t and IRF4, which control Th17 differentiation (46, 47), as well as the activation of STAT factors and ERK kinases under conditions which induce either Th17 (CD3/CD28/TGF-␤1 plus IL-6) or Treg (CD3/CD28/TGF-␤1) differentiation (Fig. 6C). IL-6 enhanced nuclear expression of pSTAT3 and ROR␥t but not of IRF4. Notably, expression of ROR␥t was similar and expression of IRF4 was even slightly enhanced in PKB tg cells, although they showed a reduced IL-17 production. In IL-6-treated cultures, wt cells showed the highest nuclear pSTAT3 at day 1 and declining levels until day 3, whereas in PKB tg cells pSTAT3 was strongest at day 3. Such altered kinetics between wt and PKB tg cells were also observed for pSTAT1. Under conditions supporting Th17 cell differentiation, nuclear pSTAT5 levels were elevated at day 3 in PKB tg cells. A striking change in expression was detected for pSTAT6, which was up-regulated in PKB tg cultures under Th17 and even stronger under Treg-inducing conditions on days 2 and 3. In addition, we repeatedly detected pERK in wt cells under Treg but not under Th17 differentiation conditions. In contrast, in PKB tg cells, pERK was detectable under both culture conditions. From three experiments we concluded that under Th17 conditions (on day 3), PKB tg cells show enhanced expression of pSTAT3, pSTAT1, pSTAT5, pSTAT6, and pERK but overall similar expression of ROR␥t and IRF4. Thus, the impaired IL-17 production of PKB tg cells is not correlated to a reduction in nuclear ROR␥t or IRF4 levels, but accompanied with an increased phosphorylation of ERK kinases and STAT factors. PKB signals influence the severity of EAE in wt and CD28⫺/⫺ mice Considering the effects of PKB on iTreg vs Th17 differentiation in vitro, we investigated whether PKB signals influence the development of EAE, a mouse model for human multiple sclerosis, in which Th17 cells play a vital role for disease initiation and progression (48). Therefore, we immunized wt and PKB tg mice with MOG35–55 peptide in CFA, and the development of EAE was scored until day 34 (40). PKB tg mice developed disease symptoms with a similar onset as wt mice (days 8 –9), but, interestingly, the severity of EAE was markedly milder as shown in Fig. 7A. Since PKB tg CD28⫺/⫺ T cells responded more strongly to TCR signals than CD28⫺/⫺ T cells and expanded in the presence of TGF-␤1 (Fig. 1, E and F), we also analyzed EAE in PKB tg CD28⫺/⫺ mice. Although CD28⫺/⫺ mice did not show overt clinical signs of neurodegeneration (49), importantly, PKB tg CD28⫺/⫺ mice developed severe EAE symptoms, albeit their clinical scores were lower than in wt and similar to those in PKB tg


FIGURE 5. Active PKB enhances pSTAT5 and Foxp3 expression in CD3 ⫹ TGF-␤1-treated CD4⫹ T cells. CD4⫹CD25⫺ T cells from A, wt and PKB tg, or B, CD28⫺/⫺ and PKB tg CD28⫺/⫺ mice were activated with CD3 Ab only (3 ␮g/ml) in the presence or absence of TGF-␤1 (10 ng/ml) for the indicated hours. Cytoplasmic (CE) and nuclear (NE) protein extracts were analyzed for the expression and phosphorylation of the indicated proteins. Data are representative of two to three experiments. n.s., n, Nonspecific loading control.



6131

mice (Fig. 7B). Thus, elevated PKB signals influence the outcome of EAE, leading to an amelioration or exacerbation of disease.

Discussion We show in this study that elevated PKB signals have a profound impact on the capacity of TGF-␤1 to modulate the differentiation and function of peripheral Treg and Th17 effector cells.

FIGURE 7. PKB signals alter the severity of EAE in wt and CD28⫺/⫺ mice. A and B, EAE was induced in A, wt and PKB tg mice, and B, wt, CD28⫺/⫺, and PKB tg CD28⫺/⫺ mice by immunization with MOG35–55 peptide. A, wt, n ⫽ 28; PKB tg, n ⫽ 18 mice; B, wt, CD28⫺/⫺, and PKB tg CD28⫺/⫺ each n ⫽ 5 mice. Data give the means ⫾ SEM. The difference in the median clinical scores, calculated by the Wilcoxon test, was p ⫽ 0.026 for wt and PKB tg mice (A) and p ⫽ 0.03 for CD28⫺/⫺ and PKB tg CD28⫺/⫺ mice (B).

Depending on the presence of costimulatory signals and cytokines, TGF-␤1 is able to promote the differentiation of conventional peripheral CD4⫹ T cells either to Tregs or Th17 cells. Elevated PKB signaling exerted two notable effects on this lineage antagonism: 1) It promoted the induction of the Treg marker Foxp3 and 2) impaired the IL-6/TGF-␤1-mediated generation of Th17 cells. By supporting Foxp3 induction and the proliferative capacity, PKB signals conferred a suppressor function to conventional T cells from wt and CD28⫺/⫺ mice stimulated by TGF-␤1 and CD3 Ab only and, thereby, converted those cells to iTregs. This indicates that TCR plus PKB plus TGF␤1 signals are sufficient to drive CD4⫹CD25⫺ T cells into the Treg lineage. Thus, PKB signaling can replace CD28 signals, which otherwise are required for the de novo differentiation of iTregs from naive T cells (9, 50). Therefore, we assume that the increase in number of peripheral nTregs in PKB tg and PKB tg CD28⫺/⫺ mice can arise by two mechanisms, i.e., by a PKB-mediated promotion of homeostatic expansion/survival of nTregs or by facilitating iTreg induction. The second remarkable feature of elevated PKB signaling on TGF-␤1-mediated lineage decision is that it strongly reduced TGF-␤1/IL-6-mediated differentiation of CD4⫹ T cells into the Th17 lineage and supported the generation of Foxp3⫹ cells. Mechanisms of PKB-mediated inhibition of IL-17 production could involve direct or indirect mechanisms. Cytokines like IFN-␥, IL-4 (14, 51), and metabolites like retinoic acid (52) oppose Th17 differentiation, whereas IRF4 or ROR␥t reinforce the differentiation and function of Th17 cells (53). Also, in several reports, an important role for IL-2 in enhancing Foxp3 and restraining Th17 production has been demonstrated (54, 55). Mice expressing a constitutively active STAT5 transgene have increased nTreg numbers in the thymus and periphery (56, 57) and STAT5, STAT3, Smad3,


FIGURE 6. Elevated PKB signals impair the differentiation into Th17 cells. A and B, CD4⫹CD25⫺ T cells from wt and PKB tg mice were cultured with CD3/CD28 Abs (2 and 5 ␮g/ml) and TGF-␤1 (10 ng/ml) in the presence or absence of IL-6 (20 ng/ml) for 3 days. A, Expression of Foxp3 and IL-17 was determined by flow cytometry. Numbers in the quadrants of the dot plots give the percentage of Foxp3⫹ and IL-17⫹ cells. Graphs show mean percentage and cell number ⫹ SD for Foxp3⫹ and IL-17⫹ cells from four independent experiments. B, Percentage and cell number of IFN-␥-, IL-10-, and IL-4producing cells from three and two independent experiments, respectively. C, CD4⫹CD25⫺ T cells from wt and PKB tg mice were cultured as described in A for the indicated days. Nuclear (NE) and cytoplasmic (CE) protein extracts were analyzed for the indicated proteins by Western blot.

6132

retain IL-2 dependence for proliferation and show enhanced suppressor activity. Interestingly, Delgoffe et al. (64) recently showed that T cells deficient in the GTPase Rheb retained mTORC2 signaling and differentiated into Tregs when stimulated in the presence of TGF-␤ despite increased phosphorylation of PKB. Therefore, it is conceivable that PKB signals exert differential effects, either enhancing or inhibiting Treg formation, depending on the timing and strength of TCR, PKB, and TGF-␤ signals induced during T cell activation. Another major finding of the present study is that conventional T cells with elevated PKB activity are less susceptible to inhibition by TGF-␤1 with regard to proliferation as well as suppression by wt and PKB tg nTregs, which inhibited conventional wt T cells more strongly than wt nTregs. This emphasizes that the activation status of PKB in conventional T cells is a primary determinant of T cell sensitivity to Treg-mediated suppression and that elevated PKB signals confer resistance within a range of suppressive capacity. The resistance of conventional T cells to Treg-mediated suppression is considered as a mechanism that plays a significant role in autoimmunity development (65). For instance, mice deficient for the E3 ubiquitin ligases Cbl-b or TNFR-associated factor 6 develop autoimmunity, although the number or function of Tregs remained unaffected, but conventional T cells are resistant to Tregmediated suppression in vitro. Furthermore, conventional T cells from NFATc2 and NFATc3 double-deficient mice (66), T cells deficient in SHIP (67), or cultured in the presence of IL-4 (68) are less inhibited by nTregs. The resistance of PKB tg cells stimulated with CD3 Ab only to TGF-␤1-mediated inhibition of proliferation was linked to the maintenance of STAT5 signaling. The underlying mechanisms for this are presently unresolved, but since STAT5 activation is critically dependent on the phosphorylation of three key tyrosines within the IL-2R␤ chain (56, 57, 69), the activation of JAK kinases and negative regulators of the suppressor of cytokine signaling family (70), it is possible that PKB signals might modulate these events. Finally, PKB tg mice showed an amelioration of EAE disease, which could correlate, among other factors, with the inhibitory effects of elevated PKB signals on the differentiation of Th17 cells in vivo. Otherwise, in the case of CD28⫺/⫺ mice, elevated PKB signals led to the induction of EAE, suggesting that elevated PKB signals override missing CD28 costimulation. Since induction of EAE in CD28⫺/⫺ mice was observed in various models (71–74), elevated PKB signals might result in enhanced activation, expansion, or survival of autoreactive T cells and an overall shift of the Th17:Treg ratio toward Th17 cells. Thus, PKB signals can exert beneficial effects on immune tolerance but also abrogate tolerogenic mechanisms and, therefore, enhance autoimmune diseases, uncovering a so far unrecognized role of PKB in influencing the balance between immune activation and suppression that is responsible for maintaining immune homeostasis.

Acknowledgments We thank F. Lu¨hder and A. Rudensky for providing CD28⫺/⫺ and Foxp3GFP mice, G. Weitz for technical assistance, and E. Serfling for helpful discussion.

Disclosures The authors have no financial conflict of interest.

References 1. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775–787. 2. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057–1061.


and NFAT are key signals in Foxp3 expression (58 – 60). Therefore, induction of Smad proteins, NFAT, and STAT5 at appropriate levels and over a sustained time period, as resulting from enhanced PKB signaling in concert with CD3 plus TGF-␤1 signals, seems to be critical for the maintenance of Foxp3 expression and differentiation into Tregs. Interestingly, IRF4 or ROR␥t expression were similar in CD3/CD28 plus TGF␤1 stimulated wt and PKB tg cells cultured in the presence of IL-6, i.e., under Th17-inducing conditions, but nuclear pSTAT5 and pSTAT3 and pSTAT1 (at day 3) were enhanced in PKB tg cells, which would contribute to promoting differentiation into the Foxp3 lineage in PKB tg cells (61, 62). Furthermore, we show that in contrast to Th17 differentiation iTreg formation involves stronger ERK signaling and that PKB signals maintain strong nuclear pSTAT6. Thus, enhanced pERK and pSTAT6 signals detected in PKB tg cells under Th17 culture conditions may impose additional limitations on IL-17 and instead support iTreg formation. Although elevated PKB signals markedly affected the Treg/ Th17 lineage decision, they appeared to be dispensable for the development of nTregs: tg PKB signals did neither influence the generation of nTregs in wt mice nor were they sufficient to fully compensate for CD28 deficiency. This shows that CD28 signals are required for optimal development of nTregs in thymus. T cellspecific deletion of the phosphatase PTEN, which enhances PI3K/ PKB signaling, did not affect thymic development of CD4⫹ Foxp3⫹ Tregs either (30), supporting our finding that elevated PKB signals leave nTreg development unaffected. However, whereas peripheral nTregs deficient for PTEN expanded by IL-2 alone, myrPKB tg nTregs did not expand in response to IL-2 and proliferated as well as wt nTregs upon CD3/CD28 plus IL-2 stimulation. Reduced numbers of peripheral nTregs, with an enhanced response to IL-2 but a compromised suppressor activity, were found in PI3K␦ kinase inactive mice (27), suggesting that signaling events downstream of PI3K are required for establishing an effective suppressor capacity in nTregs. In this line, we found that nTregs from PKB tg mice are not compromised in suppressor activity but showed an enhanced suppressive capacity. This may involve altered TCR sensitivity and/or enhanced activation of various TCR downstream signaling molecules as we described previously for PKB tg CD4⫹ T cells (37, 38). Although the precise mechanisms underlying the elevated suppressive capacity of PKB tg nTregs are presently unclear, our data indicate a specific role for PKB in enhancing Treg-mediated suppression. Some of our results appear to be in conflict with reports published recently. Upon retroviral transfer of myrPKB or using pharmacological inhibitors, it has been reported that elevated PKB signals inhibit thymic development and function of nTregs (28, 31, 32). It seems difficult to reconcile these results, but they might arise from differences in the level and timing of PKB expression and the experimental systems used. Since we showed previously that myrPKB signals affected thymic selection processes (37, 63), differences in PKB activity in the two model systems investigated could drive double-positive thymocytes with high-affinity TCRs either into apoptosis or nTreg differentiation. Haxhinasto et al. (31) showed that inhibition of Foxp3 by retrovirally transduced myrPKB was most pronounced early after T cell activation. PKB tg CD4⫹ T cells may have passed or have lower PKB signals at that critical time window of possible inhibition. In this line, we find that resting nTregs from PKB tg mice have reduced levels of CTLA4 and show a reduced PKB signaling compared with PKB tg conventional T cells. Therefore, compensatory mechanisms and down-regulation of PKB activity to thresholds appropriate for nTreg development seem to occur in PKB tg cells. Indeed, limited PKB signaling in PKB tg nTregs might be the reason that they



32. Sauer, S., L. Bruno, A. Hertweck, D. Finlay, M. Leleu, M. Spivakov, Z. A. Knight, B. S. Cobb, D. Cantrell, E. O’Connor, et al. 2008. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 105: 7797–7802. 33. Battaglia, M., A. Stabilini, and M. G. Roncarolo. 2005. Rapamycin selectively expands CD4⫹CD25⫹FoxP3⫹ regulatory T cells. Blood 105: 4743– 4748. 34. Lee, Y. K., R. Mukasa, R. D. Hatton, and C. T. Weaver. 2009. Developmental plasticity of Th17 and Treg cells. Curr. Opin. Immunol. 21: 274 –280. 35. Miyara, M., Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. Valeyre, et al. 2009. Functional delineation and differentiation dynamics of human CD4⫹ T cells expressing the FoxP3 transcription factor. Immunity 30: 899 –911. 36. Rathmell, J. C., R. L. Elstrom, R. M. Cinalli, and C. B. Thompson. 2003. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol. 33: 2223–2232. 37. Na, S. Y., A. Patra, Y. Scheuring, A. Marx, M. Tolaini, D. Kioussis, B. A. Hemmings, T. Hunig, and U. Bommhardt. 2003. Constitutively active protein kinase B enhances Lck and Erk activities and influences thymocyte selection and activation. J. Immunol. 171: 1285–1296. 38. Patra, A. K., S. Y. Na, and U. Bommhardt. 2004. Active protein kinase B regulates TCR responsiveness by modulating cytoplasmic-nuclear localization of NFAT and NF-␬B proteins. J. Immunol. 172: 4812– 4820. 39. Fontenot, J. D., J. P. Rasmussen, M. A. Gavin, and A. Y. Rudensky. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6: 1142–1151. 40. Preller, V., A. Gerber, S. Wrenger, M. Togni, D. Marguet, J. Tadje, U. Lendeckel, C. Rocken, J. Faust, K. Neubert, et al. 2007. TGF-␤1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J. Immunol. 178: 4632– 4640. 41. Fleming, K. K., J. A. Bovaird, M. C. Mosier, M. R. Emerson, S. M. LeVine, and J. G. Marquis. 2005. Statistical analysis of data from studies on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 170: 71– 84. 42. Edinger, A. L., and C. B. Thompson. 2002. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13: 2276 –2288. 43. Kelly, A. P., D. K. Finlay, H. J. Hinton, R. G. Clarke, E. Fiorini, F. Radtke, and D. A. Cantrell. 2007. Notch-induced T cell development requires phosphoinositide-dependent kinase 1. EMBO J. 26: 3441–3450. 44. Green, J. M., P. J. Noel, A. I. Sperling, T. L. Walunas, G. S. Gray, J. A. Bluestone, and C. B. Thompson. 1994. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1: 501–508. 45. Tone, Y., K. Furuuchi, Y. Kojima, M. L. Tykocinski, M. I. Greene, and M. Tone. 2008. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9: 194 –202. 46. Ivanov, I. I., B. S. McKenzie, L. Zhou, C. E. Tadokoro, A. Lepelley, J. J. Lafaille, D. J. Cua, and D. R. Littman. 2006. The orphan nuclear receptor ROR␥t directs the differentiation program of proinflammatory IL-17⫹ T helper cells. Cell 126: 1121–1133. 47. Brustle, A., S. Heink, M. Huber, C. Rosenplanter, C. Stadelmann, P. Yu, E. Arpaia, T. W. Mak, T. Kamradt, and M. Lohoff. 2007. The development of inflammatory TH-17 cells requires interferon-regulatory factor 4. Nat. Immunol. 8: 958 –966. 48. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGF␤ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179 –189. 49. Chang, T. T., C. Jabs, R. A. Sobel, V. K. Kuchroo, and A. H. Sharpe. 1999. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J. Exp. Med. 190: 733–740. 50. Guo, F., C. Iclozan, W. K. Suh, C. Anasetti, and X. Z. Yu. 2008. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J. Immunol. 181: 2285–2291. 51. Dong, C. 2008. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. 8: 337–348. 52. Elias, K. M., A. Laurence, T. S. Davidson, G. Stephens, Y. Kanno, E. M. Shevach, and J. J. O’Shea. 2008. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111: 1013–1020. 53. Ivanov, I. I., L. Zhou, and D. R. Littman. 2007. Transcriptional regulation of Th17 cell differentiation. Semin. Immunol. 19: 409 – 417. 54. Laurence, A., C. M. Tato, T. S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R. B. Blank, F. Meylan, R. Siegel, L. Hennighausen, et al. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371–381. 55. Zeiser, R., and R. S. Negrin. 2008. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 7: 458 – 462. 56. Burchill, M. A., J. Yang, C. Vogtenhuber, B. R. Blazar, and M. A. Farrar. 2007. IL-2 receptor ␤-dependent STAT5 activation is required for the development of Foxp3⫹ regulatory T cells. J. Immunol. 178: 280 –290. 57. Burchill, M. A., J. Yang, K. B. Vang, J. J. Moon, H. H. Chu, C. W. Lio, A. L. Vegoe, C. S. Hsieh, M. K. Jenkins, and M. A. Farrar. 2008. Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity 28: 112–121. 58. Chuvpilo, S., E. Jankevics, D. Tyrsin, A. Akimzhanov, D. Moroz, M. K. Jha, J. Schulze-Luehrmann, B. Santner-Nanan, E. Feoktistova, T. Konig, et al. 2002. Autoregulation of NFATc1/A expression facilitates effector T cells to escape from rapid apoptosis. Immunity 16: 881– 895.


3. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4⫹CD25⫹ regulatory T cells. Nat. Immunol. 4: 330 –336. 4. Khattri, R., T. Cox, S. A. Yasayko, and F. Ramsdell. 2003. An essential role for Scurfin in CD4⫹CD25⫹ T regulatory cells. Nat. Immunol. 4: 337–342. 5. Walker, L. S., A. Chodos, M. Eggena, H. Dooms, and A. K. Abbas. 2003. Antigen-dependent proliferation of CD4⫹CD25⫹ regulatory T cells in vivo. J. Exp. Med. 198: 249 –258. 6. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl. 2003. Conversion of peripheral CD4⫹CD25⫺ naive T cells to CD4⫹CD25⫹ regulatory T cells by TGF-␤ induction of transcription factor Foxp3. J. Exp. Med. 198: 1875–1886. 7. Apostolou, I., and H. von Boehmer. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199: 1401–1408. 8. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6: 1219 –1227. 9. Liang, S., P. Alard, Y. Zhao, S. Parnell, S. L. Clark, and M. M. Kosiewicz. 2005. Conversion of CD4⫹CD25⫺ cells into CD4⫹CD25⫹ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201: 127–137. 10. Zheng, Y., and A. Y. Rudensky. 2007. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8: 457– 462. 11. Zheng, S. G., J. D. Gray, K. Ohtsuka, S. Yamagiwa, and D. A. Horwitz. 2002. Generation ex vivo of TGF-␤-producing regulatory T cells from CD4⫹CD25⫺ precursors. J. Immunol. 169: 4183– 4189. 12. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-␤ regulation of immune responses. Annu. Rev. Immunol. 24: 99 –146. 13. Stockinger, B., M. Veldhoen, and B. Martin. 2007. Th17 T cells: linking innate and adaptive immunity. Semin. Immunol. 19: 353–361. 14. Korn, T., E. Bettelli, M. Oukka, and V. K. Kuchroo. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27: 485–517. 15. Bensinger, S. J., P. T. Walsh, J. Zhang, M. Carroll, R. Parsons, J. C. Rathmell, C. B. Thompson, M. A. Burchill, M. A. Farrar, and L. A. Turka. 2004. Distinct IL-2 receptor signaling pattern in CD4⫹CD25⫹ regulatory T cells. J. Immunol. 172: 5287–5296. 16. Hickman, S. P., J. Yang, R. M. Thomas, A. D. Wells, and L. A. Turka. 2006. Defective activation of protein kinase C and Ras-ERK pathways limits IL-2 production and proliferation by CD4⫹CD25⫹ regulatory T cells. J. Immunol. 177: 2186 –2194. 17. Li, L., W. R. Godfrey, S. B. Porter, Y. Ge, C. H. June, B. R. Blazar, and V. A. Boussiotis. 2005. CD4⫹CD25⫹ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106: 3068 –3073. 18. Jones, R. G., M. Parsons, M. Bonnard, V. S. Chan, W. C. Yeh, J. R. Woodgett, and P. S. Ohashi. 2000. Protein kinase B regulates T lymphocyte survival, nuclear factor ␬B activation, and Bcl-xL levels in vivo. J. Exp. Med. 191: 1721–1734. 19. Avota, E., A. Avots, S. Niewiesk, L. P. Kane, U. Bommhardt, V. ter Meulen, and S. Schneider-Schaulies. 2001. Disruption of Akt kinase activation is important for immunosuppression induced by measles virus. Nat. Med. 7: 725–731. 20. Cantrell, D. 2002. Protein kinase B (Akt) regulation and function in T lymphocytes. Semin. Immunol. 14: 19 –26. 21. Kane, L. P., and A. Weiss. 2003. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol. Rev. 192: 7–20. 22. Brazil, D. P., Z. Z. Yang, and B. A. Hemmings. 2004. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29: 233–242. 23. Tai, X., M. Cowan, L. Feigenbaum, and A. Singer. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 6: 152–162. 24. Salomon, B., D. J. Lenschow, L. Rhee, N. Ashourian, B. Singh, A. Sharpe, and J. A. Bluestone. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4⫹CD25⫹ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431– 440. 25. Liu, Y., S. Amarnath, and W. Chen. 2006. Requirement of CD28 signaling in homeostasis/survival of TGF-␤ converted CD4⫹CD25⫹ Tregs from thymic CD4⫹CD25⫺ single positive T cells. Transplantation 82: 953–964. 26. Golovina, T. N., T. Mikheeva, M. M. Suhoski, N. A. Aqui, V. C. Tai, X. Shan, R. Liu, R. R. Balcarcel, N. Fisher, B. L. Levine, et al. 2008. CD28 costimulation is essential for human T regulatory expansion and function. J. Immunol. 181: 2855–2868. 27. Patton, D. T., O. A. Garden, W. P. Pearce, L. E. Clough, C. R. Monk, E. Leung, W. C. Rowan, S. Sancho, L. S. Walker, B. Vanhaesebroeck, and K. Okkenhaug. 2006. Cutting edge: the phosphoinositide 3-kinase p110 ␦ is critical for the function of CD4⫹CD25⫹Foxp3⫹ regulatory T cells. J. Immunol. 177: 6598 – 6602. 28. Crellin, N. K., R. V. Garcia, and M. K. Levings. 2007. Altered activation of AKT is required for the suppressive function of human CD4⫹CD25⫹ T regulatory cells. Blood 109: 2014 –2022. 29. Zeiser, R., D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J. Z. Hou, and R. S. Negrin. 2008. Differential impact of mammalian target of rapamycin inhibition on CD4⫹CD25⫹Foxp3⫹ regulatory T cells compared with conventional CD4⫹ T cells. Blood 111: 453– 462. 30. Walsh, P. T., J. L. Buckler, J. Zhang, A. E. Gelman, N. M. Dalton, D. K. Taylor, S. J. Bensinger, W. W. Hancock, and L. A. Turka. 2006. PTEN inhibits IL-2 receptor-mediated expansion of CD4⫹CD25⫹ Tregs. J. Clin. Invest. 116: 2521–2531. 31. Haxhinasto, S., D. Mathis, and C. Benoist. 2008. The AKT-mTOR axis regulates de novo differentiation of CD4⫹Foxp3⫹ cells. J. Exp. Med. 205: 565–574.

6133

6134

67.

68.

69.

70. 71.

72.

73.

74.

factors play a crucial role in suppression of CD4⫹ T lymphocytes by CD4⫹CD25⫹ regulatory T cells. J. Exp. Med. 201: 181–187. Locke, N. R., S. J. Patterson, M. J. Hamilton, L. M. Sly, G. Krystal, and M. K. Levings. 2009. SHIP regulates the reciprocal development of T regulatory and Th17 cells. J. Immunol. 183: 975–983. Pillemer, B. B., Z. Qi, B. Melgert, T. B. Oriss, P. Ray, and A. Ray. 2009. STAT6 activation confers upon T helper cells resistance to suppression by regulatory T cells. J. Immunol. 183: 155–163. Yu, A., L. Zhu, N. H. Altman, and T. R. Malek. 2009. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30: 204 –217. Malek, T. R. 2008. The biology of interleukin-2. Annu. Rev. Immunol. 26: 453– 479. Girvin, A. M., M. C. Dal Canto, L. Rhee, B. Salomon, A. Sharpe, J. A. Bluestone, and S. D. Miller. 2000. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164: 136 –143. Chitnis, T., N. Najafian, K. A. Abdallah, V. Dong, H. Yagita, M. H. Sayegh, and S. J. Khoury. 2001. CD28-independent induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 107: 575–583. Girvin, A. M., M. C. Dal Canto, and S. D. Miller. 2002. CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J. Autoimmun. 18: 83–94. King, C. G., J. L. Buckler, T. Kobayashi, J. R. Hannah, G. Bassett, T. Kim, E. L. Pearce, G. G. Kim, L. A. Turka, and Y. Choi. 2008. Cutting edge: requirement for TRAF6 in the induction of T cell anergy. J. Immunol. 180: 34 –38.


59. Serfling, E., S. Klein-Hessling, A. Palmetshofer, T. Bopp, M. Stassen, and E. Schmitt. 2006. NFAT transcription factors in control of peripheral T cell tolerance. Eur. J. Immunol. 36: 2837–2843. 60. Hu, H., I. Djuretic, M. S. Sundrud, and A. Rao. 2007. Transcriptional partners in regulatory T cells: Foxp3, Runx and NFAT. Trends Immunol. 28: 329 –332. 61. Pallandre, J. R., E. Brillard, G. Crehange, A. Radlovic, J. P. Remy-Martin, P. Saas, P. S. Rohrlich, X. Pivot, X. Ling, P. Tiberghien, and C. Borg. 2007. Role of STAT3 in CD4⫹CD25⫹FOXP3⫹ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J. Immunol. 179: 7593–7604. 62. Kasprzycka, M., M. Marzec, X. Liu, Q. Zhang, and M. A. Wasik. 2006. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl. Acad. Sci. USA 103: 9964 –9969. 63. Masse, G. X., E. Corcuff, H. Decaluwe, U. Bommhardt, O. Lantz, J. Buer, and J. P. Di Santo. 2007. ␥ Cytokines provide multiple homeostatic signals to naive CD4⫹ T cells. Eur. J. Immunol. 37: 2606 –2616. 64. Delgoffe, G. M., T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, and J. D. Powell. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832– 844. 65. Wohlfert, E. A., and R. B. Clark. 2007. “Vive la Resistance!”: the PI3K-Akt pathway can determine target sensitivity to regulatory T cell suppression. Trends Immunol. 28: 154 –160. 66. Bopp, T., A. Palmetshofer, E. Serfling, V. Heib, S. Schmitt, C. Richter, M. Klein, H. Schild, E. Schmitt, and M. Stassen. 2005. NFATc2 and NFATc3 transcription
